Summary & Overview
HCPCS Level II J0578: Buprenorphine Extended-Release Injection, 7–28 Days
HCPCS Level II code J0578 denotes an injection of buprenorphine extended release (Brixadi) for greater than 7 days and up to 28 days of therapy. This long-acting injectable formulation is an important pharmacotherapy option in the national response to opioid use disorder because it provides extended coverage per administration, supports adherence, and reduces the need for daily dosing. The code is used when billing for the medication and its administration over a multi-week dosing interval.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and policy-relevant context for coverage and coding of long-acting buprenorphine injectables, including typical sites of service and clinical context for use. The publication outlines reimbursement benchmarks where available, common billing considerations, and policy updates that affect payer coverage and prior authorization practices. Clinical context covers the role of extended-release buprenorphine in maintenance therapy, dosing interval implications, and implications for care coordination in outpatient and behavioral health settings.
This summary is written for a national audience and focuses on coding, payer coverage landscape, and operational considerations for facilities and clinicians that administer long-acting buprenorphine injections.
Billing Code Overview
HCPCS Level II code J0578 describes an injection of buprenorphine extended release (Brixadi) intended for greater than 7 days and up to 28 days of therapy. This code represents a long-acting injectable formulation of buprenorphine used for maintenance treatment of opioid use disorder.
-
Service type: Medication administration (long-acting injectable pharmacotherapy)
-
Typical site of service: Outpatient clinic, ambulatory care setting, or behavioral health clinic where medication-assisted treatment is delivered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with moderate to severe opioid use disorder receiving monthly extended‑release buprenorphine (Brixadi) injection for maintenance therapy. The patient presents to an outpatient addiction medicine clinic or ambulatory infusion center for medication administration. Pre‑visit workflow includes verification of prior authorization, review of recent urine drug screen and clinical stability, informed consent discussion about risks and benefits, and assessment for contraindications (severe respiratory depression, hypersensitivity). At the visit, a licensed prescriber orders J0578 for a dose covering greater than 7 days and up to 28 days. A registered nurse performs medication preparation per product guidelines, confirms identity and vaccination/allergy history, administers the subcutaneous injection, monitors the patient for a short observation period for injection‑related reactions or precipitated withdrawal, documents lot number and expiration, and updates the patient’s medication administration record. Billing is submitted using HCPCS Level II code J0578 with applicable modifier(s) to indicate circumstances such as multiple procedures, billing exceptions, or discarded drug portions. Typical sites of service are outpatient clinic, ambulatory infusion center, or behavioral health clinic with capability for parenteral medication delivery.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |